Viewing Study NCT00006183



Ignite Creation Date: 2024-05-05 @ 10:00 AM
Last Modification Date: 2024-10-26 @ 9:05 AM
Study NCT ID: NCT00006183
Status: COMPLETED
Last Update Posted: 2016-07-29
First Post: 2000-08-21

Brief Title: Comparison of Hematocrit Levels in Infant Heart Surgery
Sponsor: National Heart Lung and Blood Institute NHLBI
Organization: National Heart Lung and Blood Institute NHLBI

Study Overview

Official Title: Hematocrit Strategy in Infant Heart Surgery
Status: COMPLETED
Status Verified Date: 2008-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to compare the effects of diluted hematocrit HCT levels of 35 versus 25 during hypothermic cardiopulmonary bypass CPB in infants with d-transposition of the great arteries a malformation of the heart vessels
Detailed Description: BACKGROUND

The optimal degree of hemodilution during profoundly hypothermic CPB remains controversial and widely dissimilar hemodilution studies have evolved at centers that perform infant cardiac surgery HCT a measurement of the volume of red blood cells is of interest in cardiopulmonary bypass Higher HCT levels expose individuals to the risks of microvascular occlusion blockage in the small blood vessels while lower HCT levels may critically limit oxygen delivery to the brain and other organs Preliminary research suggests that higher HCT levels provide superior brain and myocardial protection but there have not been any studies that report on outcomes after usage of higher versus lower HCT levels

DESIGN NARRATIVE

In this single-center prospective randomized study hemodilution to a HCT level of 35 versus 25 will be compared with respect to neurodevelopmental outcome and early postoperative course in infants with congenital heart disease The first aim of this study will test the hypothesis that hemodilution to a HCT level of 35 compared to a level of 25 will be associated with superior central nervous system protection The primary outcome variable will be developmental outcome at age 1 year assessed using the Bayley Scales of Infant Development Secondary outcome variables include the following 1 tissue release of S-100 protein as a measure of cerebral cellular injury 2 cerebral hemodynamics and oxygenation determined by near infrared spectroscopy NIRS 3 intrinsic cerebral vasoregulation measured by NIRS and transcranial Doppler and 4 at age 1 year neurologic examination the MacArthur inventory and structural and volumetric findings of magnetic resonance imaging MRI

The second aim of this study will test the hypothesis that hemodilution to a HCT level of 35 compared to a level of 25 will be associated with better early postoperative cardiovascular status The primary outcome measure will be serum lactate levels 1 hour after the surgery Secondary outcome measures will include the following 1 the duration of postoperative endotracheal intubation ICU stay and hospital stay 2 serum lactate levels 3 the PaO2FiO2 ratio 4 levels of circulating pro-inflammatory cytokines and 5 the percent change in total body water estimated by bioelectrical impedance The structure of the study will allow assessment of whether 1-year outcomes can be predicted by perioperative variables other than the HCT strategies Through the use of novel techniques such as NIRS and volumetric MRI the study may also provide insight into mechanisms by which HCT and other perioperative variables affect the brain The information obtained from this study should be broadly generalized to infants with other forms of congenital heart disease undergoing early repair and should have substantial impact on clinical practice

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
U01HL063411 NIH None httpsreporternihgovquickSearchU01HL063411